Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat + Bevacizumab in Metastatic Renal Cell Carcinoma
NCT00324870Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2006
- Primary completion
- Jun 2013
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in clear cell renal cell carcinoma (ccRCC), sponsored by National Cancer Institute. Started Feb 2006; status: completed.
02
Drugs
vorinostat
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT00324870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00324870.